Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen Posts 134-Percent Q3 Revenue Growth as Losses Rise 34 Percent

NEW YORK (GenomeWeb News) — Nanogen yesterday reported that third-quarter revenues bolted upwards 134 percent on dramatic increases in product sales, but the company posted a 34-percent increase in net loss.
 
Total receipts for the quarter ended Sept. 30 increased to $7.5 million from $3.2 million year over year.
 
R&D spending in the quarter doubled to $6.2 million, Nanogen said.
 
Nanogen said net losses for the period swelled to $11.8 million from $8.8 million year over year.
 
The company said it had around $32.8 million in cash, equivalents, and short-term investments as of Sept. 30.
 
Nanogen, which last month said it would cut its US headcount by 15 percent by the end of the year in an effort to improve profits, also said it was working to integrate some acquisitions. Among them are Epoch Biosciences, SynX, and Spectral Diagnostics’ cardiac assets.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.